Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Quinidine sulfate
Drug ID BADD_D01894
Description An optical isomer of [quinine], extracted from the bark of the Cinchona tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular action potential, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.
Indications and Usage For the treatment of ventricular pre-excitation and cardiac dysrhythmias
Marketing Status approved; investigational
ATC Code C01BA01
DrugBank ID DB00908
KEGG ID D02272
MeSH ID D011802
PubChem ID 11069
TTD Drug ID Not Available
NDC Product Code 12065-1701; 0185-1047; 0185-4346; 49452-6180
UNII J13S2394HE
Synonyms Quinidine | Chinidin | Apo-Quinidine | Apo Quinidine | Quinora | Quinidex | Quinidine Sulfate | Sulfate, Quinidine | Adaquin | Quincardine
Chemical Information
Molecular Formula C20H26N2O6S
CAS Registry Number 50-54-4
SMILES COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.OS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Sjogren's syndrome06.08.02.011; 15.06.01.015; 10.04.04.009; 07.06.01.010--Not Available
Sleep disorder19.02.04.001--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Systemic lupus erythematosus10.04.03.004; 23.03.02.006; 15.06.02.003--Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tremor17.01.06.002--
Urticaria23.04.02.001; 10.01.06.001--
Uveitis10.02.01.023; 06.04.03.003--
Vasculitis24.12.04.027; 10.02.02.006--
Ventricular extrasystoles02.03.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Musculoskeletal discomfort15.03.04.001--Not Available
Nodule08.03.05.002--Not Available
Dermatitis psoriasiform23.03.14.004--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Psychotic disorder19.03.01.002--
Pigmentation disorder23.05.03.001--Not Available
Skeletal muscle enzymes13.04.01.008--Not Available
Exfoliative rash23.03.07.006--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages